Aurora Cannabis’s (TSX: ACB) C$1.23 billion Acquisition of CanniMed
Aurora Cannabis Inc. (TSX: ACB) (OTCQX: ACBFF), a Canadian based public company, announced a C$1.23-billion-dollar transaction, in cash and stock, to acquire CanniMed Inc. (TMX: CMED). This marks one of the largest deals ever made in the public or private cannabis and industrial hemp sectors.
Canopy Growth Corp (TSX: WEED) Officially Completes Raise of $200M in Funding
Canopy Growth Corp (TSX: WEED) announced the company has raised $200,680,000 by selling a total of 5,800,000 common shares at $34.60 per share. The financing was led by co-led by GMP Securities L.P. and BMO Capital Markets and including Canaccord Genuity Corp., Eight Capital, Beacon Securities Limited, and PI Financial Corp.
Canadian Company Aphria (TSE: APH) Purchases Nuuvera for $826M to Create International Powerhouse
Nuuvera already has operations setup in England, Germany, Israel, Italy, Spain, and Uruguay which is an enticing selling point to any public company attempting to widen the margins of their footprint on industry. This opens the door for key acquisitions of other companies in the space around the world. Aphira also, already has an existing agreement in Australia by purchasing 25% of Althea, an Austrialian medical cannabis producer.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…